-
1
-
-
50649085243
-
Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases
-
Castells MC, Tennant NM, Sloane DE. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008;122:574-80.
-
(2008)
J Allergy Clin Immunol
, vol.122
, pp. 574-580
-
-
Castells, M.C.1
Tennant, N.M.2
Sloane, D.E.3
-
2
-
-
0032930930
-
Clinical features of hypersensitivity reactions to carboplatin
-
Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999;17:1141-5. (Pubitemid 29162937)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.4
, pp. 1141-1145
-
-
Markman, M.1
Kennedy, A.2
Webster, K.3
Elson, P.4
Peterson, G.5
Kulp, B.6
Belinson, J.7
-
3
-
-
0033986063
-
Paclitaxel-associated hypersensitivity reactions: Experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer Center
-
Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol. 2000;18:102-5. (Pubitemid 30036342)
-
(2000)
Journal of Clinical Oncology
, vol.18
, Issue.1
, pp. 102-105
-
-
Markman, M.1
Kennedy, A.2
Webster, K.3
Kulp, B.4
Peterson, G.5
Belinson, J.6
-
4
-
-
65549168690
-
Infusion reactions to monoclonal antibodies for solid tumors: Immunologic mechanisms and risk factors
-
Chung CH, O'Neil BH. Infusion reactions to monoclonal antibodies for solid tumors: immunologic mechanisms and risk factors. Oncology. 2009;23:14-7.
-
(2009)
Oncology
, vol.23
, pp. 14-17
-
-
Chung, C.H.1
O'Neil, B.H.2
-
5
-
-
84883165337
-
Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions
-
This article identified BRCA1/2 mutation carriers to be higher risk for platinum agent hypersensitivity
-
Moon DH, Lee JM, Noonan AM, Annunziata CM, Minasian L, Houston N, et al. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. Br J of Cancer. 2013;109:1072-8. This article identified BRCA1/2 mutation carriers to be higher risk for platinum agent hypersensitivity.
-
(2013)
Br J of Cancer
, vol.109
, pp. 1072-1078
-
-
Moon, D.H.1
Lee, J.M.2
Noonan, A.M.3
Annunziata, C.M.4
Minasian, L.5
Houston, N.6
-
6
-
-
78649241782
-
General considerations on rapid desensitization for drug hypersensitivity: A consensus statement
-
Cernadas JR, Brockow K, Romano A, et al. General considerations on rapid desensitization for drug hypersensitivity: a consensus statement. Allergy. 2010;65:1357-66.
-
(2010)
Allergy
, vol.65
, pp. 1357-1366
-
-
Cernadas, J.R.1
Brockow, K.2
Romano, A.3
-
7
-
-
84891656768
-
Successful outpatient graded administration of trimethoprim- sulfamethoxazole in patients without HIV and a history of sulfonamide adverse drug reaction
-
Pyle RC, Butterfield JH, Volcheck GW, Podjasek JC, Rank MA, Li JT, et al. Successful outpatient graded administration of trimethoprim-sulfamethoxazole in patients without HIV and a history of sulfonamide adverse drug reaction. J Allergy Clin Immunol Pract. 2014;2:52-8.
-
(2014)
J Allergy Clin Immunol Pract
, vol.2
, pp. 52-58
-
-
Pyle, R.C.1
Butterfield, J.H.2
Volcheck, G.W.3
Podjasek, J.C.4
Rank, M.A.5
Li, J.T.6
-
8
-
-
84866017960
-
Evaluation of basophil CD203c as a predictor of carboplatin-related hypersensitivity reaction in patients with gynecologic cancer
-
This article suggests that basophil activation test may help predict carboplatin-related anaphylaxis
-
Iwamoto T, Yuta A, Tabata T, et al. Evaluation of basophil CD203c as a predictor of carboplatin-related hypersensitivity reaction in patients with gynecologic cancer. Biol Pharm Bull. 2012;35(9):1487-95. This article suggests that basophil activation test may help predict carboplatin-related anaphylaxis.
-
(2012)
Biol Pharm Bull
, vol.35
, Issue.9
, pp. 1487-1495
-
-
Iwamoto, T.1
Yuta, A.2
Tabata, T.3
-
9
-
-
84891657716
-
Oxaliplatin hypersensitivity: Evaluation, implications of skin testing, and desensitization
-
The first large retrospective series of oxaliplatin hypersensitivity in 48 patients treated with 200 successful desensitizations
-
Wong JT, Ling M, Patil B, Banerji A, Long A. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization. J Allergy Clin Immunol Pract. 2014;2:40-5. The first large retrospective series of oxaliplatin hypersensitivity in 48 patients treated with 200 successful desensitizations.
-
(2014)
J Allergy Clin Immunol Pract
, vol.2
, pp. 40-45
-
-
Wong, J.T.1
Ling, M.2
Patil, B.3
Banerji, A.4
Long, A.5
-
10
-
-
18144392975
-
2) in the treatment of gynecologic cancers
-
DOI 10.1016/j.ygyno.2004.12.057
-
Kim RJ, Peterson G, Kulp B, et al. Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers. Gynecol Oncol. 2005;97:374-8. (Pubitemid 40614877)
-
(2005)
Gynecologic Oncology
, vol.97
, Issue.2
, pp. 374-378
-
-
Kim, R.J.1
Peterson, G.2
Kulp, B.3
Zanotti, K.M.4
Markman, M.5
-
11
-
-
0034529887
-
Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin
-
Lotem M, Lyass O, Goldenhersh MA, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol. 2000;136:1475-80. (Pubitemid 32009267)
-
(2000)
Archives of Dermatology
, vol.136
, Issue.12
, pp. 1475-1480
-
-
Lotem, M.1
Hubert, A.2
Lyass, O.3
Goldenhersh, M.A.4
Ingber, A.5
Peretz, T.6
Gabizon, A.7
-
12
-
-
1542438610
-
Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity
-
DOI 10.1200/JCO.2003.05.539
-
Markman M, Zanotti K, Peterson G, Kulp B, Webster K, Belinson J. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol. 2003;21:4611-4. (Pubitemid 46594035)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.24
, pp. 4611-4614
-
-
Markman, M.1
Zanotti, K.2
Peterson, G.3
Kulp, B.4
Webster, K.5
Belinson, J.6
-
13
-
-
73449120788
-
Carboplatin hypersensitivity: Does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study
-
Gomez R, Harter P, Luck HJ, Traut A, Kommoss S, Kandel M, et al. Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study. Int J Gynecol Cancer. 2009;19:1284-7.
-
(2009)
Int J Gynecol Cancer
, vol.19
, pp. 1284-1287
-
-
Gomez, R.1
Harter, P.2
Luck, H.J.3
Traut, A.4
Kommoss, S.5
Kandel, M.6
-
14
-
-
84856443686
-
A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions
-
Patil S, Long A, Ling M, et al. A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions. J Allergy Clin Immunol. 2012;129:443-7.
-
(2012)
J Allergy Clin Immunol
, vol.129
, pp. 443-447
-
-
Patil, S.1
Long, A.2
Ling, M.3
-
15
-
-
71349084892
-
Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment
-
Brennan PJ, Rodriguez Bouza T, Hsu F, et al. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009;124:1259-66.
-
(2009)
J Allergy Clin Immunol
, vol.124
, pp. 1259-1266
-
-
Brennan, P.J.1
Rodriguez Bouza, T.2
Hsu, F.3
-
16
-
-
84878358699
-
Allerogological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab
-
Matucci A, Pratesi S, Petroni G, et al. Allerogological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. Clin Exp Allergy. 2013;43:659-64.
-
(2013)
Clin Exp Allergy
, vol.43
, pp. 659-664
-
-
Matucci, A.1
Pratesi, S.2
Petroni, G.3
-
17
-
-
4344610304
-
Clinical features and severity grading of anaphylaxis
-
DOI 10.1016/j.jaci.2004.04.029, PII S0091674904013983
-
Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004;114:371-6. (Pubitemid 39119039)
-
(2004)
Journal of Allergy and Clinical Immunology
, vol.114
, Issue.2
, pp. 371-376
-
-
Brown, S.G.A.1
-
18
-
-
0036200063
-
Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy
-
DOI 10.1006/gyno.2001.6519
-
Dizon DS, Sabbatini PJ, Aghajanian C, et al. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development after a carboplatin allergy. Gynecol Oncol. 2002;84(3):378-82. (Pubitemid 34211861)
-
(2002)
Gynecologic Oncology
, vol.84
, Issue.3
, pp. 378-382
-
-
Dizon, D.S.1
Sabbatini, P.J.2
Aghajanian, C.3
Hensley, M.L.4
Spriggs, D.R.5
-
19
-
-
76649118099
-
Administration of cisplatin in three patients with carboplatin hypersensitivity: Is skin testing useful?
-
Syrigou E, Nektaria M, Vassias A, et al. Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful? Anti-Cancer Drugs. 2010;21:333-8.
-
(2010)
Anti-Cancer Drugs
, vol.21
, pp. 333-338
-
-
Syrigou, E.1
Nektaria, M.2
Vassias, A.3
-
20
-
-
67649171726
-
Risk stratification for desensitization of patients with carboplatin hypersensitivity: Clinical presentation and management
-
Hesterberg P, Banerji A, Oren E, et al. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol. 2009;129:1262-7.
-
(2009)
J Allergy Clin Immunol
, vol.129
, pp. 1262-1267
-
-
Hesterberg, P.1
Banerji, A.2
Oren, E.3
-
21
-
-
84883326695
-
Carboplatin, oxaliplatin and cisplatin-specific IgE: Cross reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy
-
Once validated, specific IgE may be useful in risk-stratifying patients
-
Caiado J, Pereira-Santos MC VL, Costa L, Barbosa M, Castells M. Carboplatin, oxaliplatin and cisplatin-specific IgE: cross reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. J Allergy Clin Immunol: In Practice. 2013;1:494-500. Once validated, specific IgE may be useful in risk-stratifying patients.
-
(2013)
J Allergy Clin Immunol: In Practice
, vol.1
, pp. 494-500
-
-
Caiado, J.1
Pereira-Santos, M.C.2
V, L.3
Costa, L.4
Barbosa, M.5
Castells, M.6
-
22
-
-
84880302626
-
Hypersensitivity and desensitization to antineoplastic agents: Outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment
-
A new shorter desensitization protocol
-
Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, Ferreiro-Monteagudo R, Ruillen-Ponce C, Pueyo C, et al. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy. 2013;68(7):853-61. A new shorter desensitization protocol.
-
(2013)
Allergy
, vol.68
, Issue.7
, pp. 853-861
-
-
Madrigal-Burgaleta, R.1
Berges-Gimeno, M.P.2
Angel-Pereira, D.3
Ferreiro-Monteagudo, R.4
Ruillen-Ponce, C.5
Pueyo, C.6
-
23
-
-
84867909612
-
Adverse reactions in patients with B-cell lymphomas during combined treatment with rituximab: In vitro evaluation of rituximab hypersensitivity by basophil activation test
-
This article also evaluates basophil activation test as a possible marker for predication of anaphylaxis
-
Piva E, Chieco-Bianchi F, Krajcar V, et al. Adverse reactions in patients with B-cell lymphomas during combined treatment with rituximab: in vitro evaluation of rituximab hypersensitivity by basophil activation test. Am J Hematol. 2012;87(11):E130-1. This article also evaluates basophil activation test as a possible marker for predication of anaphylaxis.
-
(2012)
Am J Hematol
, vol.87
, Issue.11
-
-
Piva, E.1
Chieco-Bianchi, F.2
Krajcar, V.3
-
24
-
-
79955134975
-
A new rapid desensitization protocol for chemotherapy agents
-
This article reviews a desensitization protocol that is shorter and a premedication regimen based on radiocontrast allergy
-
Gastaminza G, de la Borbolla JM, Goikoetxea MJ, Escudero R, Anton J, Espinos J, et al. A new rapid desensitization protocol for chemotherapy agents. J Investig Allergol Clin Immunol. 2011;21(2):108-12. This article reviews a desensitization protocol that is shorter and a premedication regimen based on radiocontrast allergy.
-
(2011)
J Investig Allergol Clin Immunol
, vol.21
, Issue.2
, pp. 108-112
-
-
Gastaminza, G.1
De La Borbolla, J.M.2
Goikoetxea, M.J.3
Escudero, R.4
Anton, J.5
Espinos, J.6
-
25
-
-
40849142102
-
Cetuximab-induced anaphylaxis and IgE specific fort galactose-α-1, 3-galactose
-
Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific fort galactose-α-1,3-galactose. N Engl J Med. 2008;358:1009-17.
-
(2008)
N Engl J Med
, vol.358
, pp. 1009-1017
-
-
Chung, C.H.1
Mirakhur, B.2
Chan, E.3
-
26
-
-
79955613976
-
The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1, 3-galactose
-
Commins SP, James HR, Kelly LA, Pochan SL, Workman LJ, Perzanowski MS, et al. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1, 3-galactose. J Allergy Clin Immunol. 2011;127(5):1286-93.
-
(2011)
J Allergy Clin Immunol
, vol.127
, Issue.5
, pp. 1286-1293
-
-
Commins, S.P.1
James, H.R.2
Kelly, L.A.3
Pochan, S.L.4
Workman, L.J.5
Perzanowski, M.S.6
-
27
-
-
77957893019
-
Drug Allergy. An updated practice parameter
-
Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology
-
Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Drug Allergy. An updated practice parameter. Ann Allergy Asthma Immunol. 2010;105(4):259-73.
-
(2010)
Ann Allergy Asthma Immunol
, vol.105
, Issue.4
, pp. 259-273
-
-
-
28
-
-
79958779443
-
Platinum agent-induced hypersensitivity reactions: Data mining of the public version of the FDA Adverse Event Reporting System
-
Sakaeda T, Kadoyama K, Yabuuchi H, Niijima S, Seki K, Shiraishi Y, et al. Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA Adverse Event Reporting System. AERS Int J Med Sci. 2011;8(4):332-8.
-
(2011)
AERS Int J Med Sci
, vol.8
, Issue.4
, pp. 332-338
-
-
Sakaeda, T.1
Kadoyama, K.2
Yabuuchi, H.3
Niijima, S.4
Seki, K.5
Shiraishi, Y.6
-
29
-
-
33750034903
-
Diagnosis and management of hypersensitivity reactions caused by oxaliplatin
-
Herrero T, Tornero P, Infante S, Fuentes V, Sanchez NM, de Barrio M, et al. Diagnosis and management of hypersensitivity reactions caused by oxaliplatin. J Investiga Allergol CLin Immunol. 2006;16(5):327-30. (Pubitemid 44580263)
-
(2006)
Journal of Investigational Allergology and Clinical Immunology
, vol.16
, Issue.5
, pp. 327-330
-
-
Herrero, T.1
Tornero, P.2
Infante, S.3
Fuentes, V.4
Sanchez, M.N.5
De Barrio, M.6
Baeza, M.L.7
-
30
-
-
60849092276
-
Acetylsalicyclic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization
-
Breslow RG, Caiado J, Castells MC. Acetylsalicyclic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. Ann Allergy Asthma Immunol. 2009;102:155-60.
-
(2009)
Ann Allergy Asthma Immunol
, vol.102
, pp. 155-160
-
-
Breslow, R.G.1
Caiado, J.2
Castells, M.C.3
-
31
-
-
79955573063
-
Immediate adverse reactions to biologicals: From pathogenic mechanisms to prophylactic management
-
Vultaggio A, Maggi E, Matucci A. Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Curr Opin Allergy Clin Immunol. 2013;11:262-8.
-
(2013)
Curr Opin Allergy Clin Immunol
, vol.11
, pp. 262-268
-
-
Vultaggio, A.1
Maggi, E.2
Matucci, A.3
-
32
-
-
84891648510
-
Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels
-
This case report presents the added benefit of using omalizumab for drug desensitization
-
Ojaimi S, Harnett PR, Fulcher DA. Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels. J Allergy Clin Immunol Pract. 2014;2:105-6. This case report presents the added benefit of using omalizumab for drug desensitization.
-
(2014)
J Allergy Clin Immunol Pract
, vol.2
, pp. 105-106
-
-
Ojaimi, S.1
Harnett, P.R.2
Fulcher, D.A.3
-
33
-
-
79953038437
-
Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcepsilonRI internalization
-
Sancho-Serra Mdel C, Simarro M, Castells M. Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcepsilonRI internalization. Eur J Immunol. 2011;41:1004-13.
-
(2011)
Eur J Immunol
, vol.41
, pp. 1004-1013
-
-
Sancho-Serra Mdel, C.1
Simarro, M.2
Castells, M.3
-
34
-
-
19044372321
-
Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen
-
Morales AR, Shah N, Castells M. Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. Ann Allergy Asthma Immunol. 2005;94:575-80. (Pubitemid 40712782)
-
(2005)
Annals of Allergy, Asthma and Immunology
, vol.94
, Issue.5
, pp. 575-580
-
-
Morales, A.R.1
Shah, N.2
Castells, M.3
-
35
-
-
84881119249
-
Successful rapid rituximab desensitization in an adolescent patient with nephrotic syndrome: Increase in number of Treg cells after desensitization
-
This case report also highlights increased in Treg cells after a successful desensitization
-
Aydogan M, Yologlu N, Gacar G, et al. Successful rapid rituximab desensitization in an adolescent patient with nephrotic syndrome: increase in number of Treg cells after desensitization. J Allergy Clin Immunol. 2013;132(2):478-80. This case report also highlights increased in Treg cells after a successful desensitization.
-
(2013)
J Allergy Clin Immunol
, vol.132
, Issue.2
, pp. 478-480
-
-
Aydogan, M.1
Yologlu, N.2
Gacar, G.3
-
36
-
-
84885765269
-
Drug desensitizations in the management of allergy and anaphylaxis to chemotherapeutic agents and monoclonal antibodies
-
Castells MC, editor. New York: Humana Press
-
Banerji A, Brennan P, Hesterberg P, et al. Drug desensitizations in the management of allergy and anaphylaxis to chemotherapeutic agents and monoclonal antibodies. In: Castells MC, editor. Anaphylaxis and Hypersensitivity Reactions. New York: Humana Press; 2011. p. 297-311.
-
(2011)
Anaphylaxis and Hypersensitivity Reactions
, pp. 297-311
-
-
Banerji, A.1
Brennan, P.2
Hesterberg, P.3
-
38
-
-
84906101183
-
-
UpToDate, Post TW (Ed), UpToDate, Waltham, MA (Accessed on December 10, 2013)
-
Castells MC, Matulonis UA. Infusion reactions to systemic chemotherapy. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA (Accessed on December 10, 2013)
-
Infusion Reactions to Systemic Chemotherapy
-
-
Castells, M.C.1
Matulonis, U.A.2
|